🇺🇸 FDA
Patent

US 12331293

Bispecific antisense oligonucleotides for dystrophin exon skipping

granted A61PA61P21/00

Quick answer

US patent 12331293 (Bispecific antisense oligonucleotides for dystrophin exon skipping) held by BIOMARIN TECHNOLOGIES B.V. expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN TECHNOLOGIES B.V.
Grant date
Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P21/00